MedTrace Logo

The Dutch Parkinson and Cognition Study

NCT04180865 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 150

Last updated 2019-11-29

No results posted yet for this study

Summary

Parkinson Disease (PD) is a heterogeneous, progressive neurodegenerative disorder which is characterized by a variety of motor and non-motor symptoms. The DUPARC study is a single-centre longitudinal cohort study aimed at deeply phenotyping newly diagnosed PD patients. The main aim is to investigate the relationship between cognitive impairment and both cholinergic and dopaminergic neurodegeneration in the early stages of the disease. In addition, gastrointestinal and visual system dysfunction in PD and their role in the underlying pathology are further explored in a longitudinal setup. Treatment-naïve participants will undergo extensive motor- and non-motor assessment, imaging, and microbiome assessment at time of diagnosis, and will be followed for at least 3 years.

Conditions

  • Parkinson Disease

Sponsors & Collaborators

  • Parkinson Platform Noord Nederland

    collaborator UNKNOWN

  • University Medical Center Groningen

    lead OTHER

Principal Investigators

  • Teus van Laar, MD PhD · University Medical Center Groningen

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2017-10-01
Primary Completion
2023-10-01
Completion
2023-10-01

Countries

  • Netherlands

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04180865 on ClinicalTrials.gov